2 Drug Stocks Gapping Lower After Earnings

Both Cowen and Stifel downgraded AKCA stock

Feb 27, 2018 at 9:28 AM
facebook twitter linkedin


Clovis Oncology Inc (NASDAQ:CLVS) last night reported an adjusted fourth-quarter loss of $1.27 per share on $17 million in revenue, with the latter number falling short of analysts' consensus estimate for $20.1 million in revenue. Wall Street was quick to chime in, too, with CLVS stock receiving price-target cuts from Barclays (to $85), BofA-Merrill Lynch (to $89), Stifel (to $110), and SunTrust Robinson (to $85). And though all of these price targets sit well above last night's close at $55.51, the shares are down 2.4% in electronic trading.

Just last week, Clovis Oncology shares rallied on positive signs for its ovarian cancer drug marketing application in the European Union (EU), but were quickly contained by their 60-day moving average. This trendline has kept a tight lid on CLVS stock since early November, with the stock now staring at a six-month deficit of nearly 25%.

There's still plenty of optimism priced into CLVS shares, though. Of the 12 analysts covering the biotech, 10 maintain a "buy" or better rating, while the average 12-month price target of $86.55 stands at a 55.9% premium to current trading levels.

Akcea Therapeutics Inc (NASDAQ:AKCA) also reported earnings last night, with the lipid disorder specialist reporting a fourth-quarter loss of 35 cents per share and revenue of $18 million. The results prompted downgrades to the equivalent of a "hold" at both Cowen and Company and Stifel, though BMO raised its price target to $30 from $25.

After closing last night at $22.58, AKCA stock is down 21.2% in electronic trading -- on track to open at its lowest point since mid-January. Short sellers were betting on a pullback, too. Short interest on Akcea Therapeutics stock shot up 48.4% in the two most recent reporting period to a record high 5.14 million shares. These bearish bettors will be sitting on the sidelines today, though, with the security all but certain to land on the short-sale restricted list.

 

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report
 


 


 
Special Offers from Schaeffer's Trading Partners